Dexmetomidine intravenously — Competitive Intelligence Brief

Dexmetomidine intravenously (Dexmetomidine intravenously) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia and Critical Care.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia and Critical Care Small molecule

Target snapshot

Dexmetomidine intravenously (Dexmetomidine intravenously) — KAT General Hospital. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexmetomidine intravenously TARGET	Dexmetomidine intravenously	KAT General Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
lofexidine HCl	lofexidine HCl	USWM, LLC (dba US WorldMeds)	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Intranasal dexmedetomidine-esketamine	Intranasal dexmedetomidine-esketamine	Peking University First Hospital	marketed	Alpha-2 adrenergic agonist / NMDA receptor antagonist combination	Alpha-2 adrenergic receptors; NMDA receptor
Combigan Two Times Daily (BID)	Combigan Two Times Daily (BID)	Cornerstone Health Care, PA	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker	Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors
brimonidine 0.1% (Alphagan® P)	brimonidine 0.1% (Alphagan® P)	Allergan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine for sedation	Dexmedetomidine for sedation	Southeast University, China	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Combined dexmedetomidine-esketamine	Combined dexmedetomidine-esketamine	Peking University First Hospital	marketed	Sedative-analgesic combination	Alpha-2 adrenergic receptor; NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

1. Allergan · 3 drugs in this class
2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
3. National Cancer Institute, Egypt · 2 drugs in this class
4. The University of Hong Kong · 2 drugs in this class
5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
6. Fayoum University Hospital · 1 drug in this class
7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
10. KAT General Hospital · 1 drug in this class